智通财经APP获悉,美国特拉华州一个联邦陪审团裁定,安进(AMGN.US)违反美国反垄断法,强迫药品福利管理机构 (PBM) 选择其胆固醇药物Repatha,而不是竞争药物Praluent,再生元制药公司(REGN.US)应获得4亿多美元的赔偿金。特拉华州地方法院的陪审团于周四做出了支持再生元制药公司的判决,指控安进非法捆绑其抗炎药Enbrel和Otezla,以说服PBM选择Repatha而不是...
Source Link智通财经APP获悉,美国特拉华州一个联邦陪审团裁定,安进(AMGN.US)违反美国反垄断法,强迫药品福利管理机构 (PBM) 选择其胆固醇药物Repatha,而不是竞争药物Praluent,再生元制药公司(REGN.US)应获得4亿多美元的赔偿金。特拉华州地方法院的陪审团于周四做出了支持再生元制药公司的判决,指控安进非法捆绑其抗炎药Enbrel和Otezla,以说服PBM选择Repatha而不是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.